Financings in Brief: ChromaVision Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
ChromaVision Medical Systems: Firm's Aug. 13 initial public offering totals approximately 7.4 mil. shares, including the sale of 640,000 overallotment shares sold by certain shareholders, the firm states. ChromaVision netted $29.2 mil. from its sale of 6,020,000 new shares at $5 each ("The Gray Sheet" Aug. 25, p. 13); shareholders sold a total of 1,020,000 additional shares, including the overallotments, and Safeguard Scientifics, which held 37.4% of the automated microscope maker prior to the offering, sold some shares but also gained 320,000 additional new shares under terms of the offering. Safeguard currently holds about 20% of the company. About 17.1 mil. shares are currently outstanding. Underwriters were Robert W. Baird & Co. and Adams, Harkness & Hill...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.